Foundayo (Orforglipron) Side Effects: Comprehensive Evidence Review

At a glance

• Foundayo is the first once-daily oral GLP-1 pill approved for chronic weight management. FDA approval was granted April 1, 2026 for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity^[4]. Unlike Rybelsus (oral semaglutide), orforglipron is a non-peptide small molecule, which makes oral absorption more reliable but does not change the underlying GLP-1 receptor agonist pharmacology.
• The pivotal ATTAIN-1 trial randomized 3,127 adults to once-daily orforglipron 6, 12, or 36 mg or placebo for 72 weeks. Mean weight loss at the 36 mg arm was -11.2% on the treatment- regimen estimand^[1]. The most common adverse events were gastrointestinal effects, mostly mild to moderate, and adverse events caused treatment discontinuation in 5.3 to 10.3% of patients in the orforglipron groups vs 2.7% on placebo.
• ATTAIN-2 confirmed the AE profile in a T2D population. Across 1,613 adults with type 2 diabetes (baseline HbA1c 8.05%), Foundayo at 36 mg produced -9.6% weight loss at 72 weeks vs -2.5% placebo, with treatment discontinuations due to adverse events of 6.1 to 9.9% on Foundayo vs 4.1% on placebo — mainly GI-related^[2].
• ATTAIN-MAINTAIN tested switching from injectable GLP-1 to oral Foundayo for maintenance. SURMOUNT-5 completers who had taken tirzepatide (cohort 1, n=205) or semaglutide (cohort 2, n=171) were randomized to oral orforglipron or placebo for 52 weeks. Foundayo preserved 74.7 to 79.3% of the prior body-weight reduction vs 37.6 to 49.2% with placebo, with adverse events again predominantly mild-to-moderate GI^[3].
• The FDA Foundayo label boxed warning is for thyroid C-cell tumors. This is a GLP-1 class label finding observed in rodents at clinically relevant exposures. Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2^[4].
• Hypoglycemia risk is narrow in monotherapy and broader in T2D combination therapy. Foundayo does not directly cause hypoglycemia in adults without diabetes. The labeled hypoglycemia risk is specific to patients with type 2 diabetes who are also on insulin or a sulfonylurea, where the GLP-1 effect on insulin secretion stacks with the secretagogue or exogenous insulin^[2][4].
• Dosing instructions matter more than for injectable GLP-1s. The Foundayo label requires once-daily dosing on an empty stomach with plain water only, with at least 30 minutes before the first food, drink, or other oral medication of the day. Skipping this window reduces absorption and can produce an unpredictable AE pattern. This is the largest practical tolerability difference vs once-weekly injectable Wegovy or Zepbound.
• Pregnancy and certain renal warnings apply. Pregnancy is contraindicated; effective contraception is required and Foundayo should be discontinued at least 2 months before a planned pregnancy. Acute kidney injury secondary to volume contraction from severe GI losses is labeled, the same class warning as for Wegovy and Zepbound^[4].

What ATTAIN-1, ATTAIN-2, and ATTAIN-MAINTAIN actually reported

The Foundayo adverse-event evidence base rests on three phase 3 randomized trials, all published in top-tier journals and all consistently describing the same broad pattern: dominant mild-to-moderate gastrointestinal effects concentrated during dose escalation, with serious adverse events that follow the GLP-1 class pattern rather than introducing any unique signal specific to the oral small-molecule mechanism.

ATTAIN-1 (Wharton and colleagues, published in the November 6, 2025 issue of the New England Journal of Medicine)^[1] randomized 3,127 adults with obesity without type 2 diabetes to once-daily oral orforglipron at 6 mg, 12 mg, or 36 mg, or placebo, in a 3:3:3:4 ratio, for 72 weeks as an adjunct to a healthy diet and physical activity. The primary endpoint was percent change in body weight from baseline to week 72, treatment-regimen estimand. The 36 mg arm produced -11.2% mean weight change (95% CI -12.0 to -10.4), the 12 mg arm -8.4%, the 6 mg arm -7.5%, vs -2.1% on placebo. Adverse events caused treatment discontinuation in 5.3 to 10.3% of orforglipron patients (dose-dependent) vs 2.7% on placebo. The most common adverse events were gastrointestinal effects, mostly mild to moderate, and the safety profile was, in the investigators’ own framing, “consistent with that of other GLP-1 receptor agonists.”

ATTAIN-2 (Horn and colleagues, published in the December 20, 2026 issue of The Lancet)^[2] was the parallel phase 3 trial in adults with obesity and type 2 diabetes (BMI ≥27, HbA1c 7-10%). Participants were randomized 1:1:1:2 to orforglipron 6 mg, 12 mg, 36 mg, or placebo for 72 weeks. Of 1,613 randomized, 1,444 (89.5%) completed. Baseline body weight was 101.4 kg, BMI 35.6, and HbA1c 8.05%. At the 36 mg arm, mean weight change at 72 weeks was -9.6% (95% CI -10.5 to -8.7), with -7.0% at 12 mg and -5.1% at 6 mg, vs -2.5% on placebo. Treatment discontinuations due to adverse events were higher with orforglipron (6.1 to 9.9%) than with placebo (4.1%), and were again predominantly gastrointestinal. The investigators reported ten deaths during the study (six on orforglipron, four on placebo), all but two adjudicated as unrelated to study treatment.

ATTAIN-MAINTAIN (Aronne and colleagues, published in the May 13, 2026 issue of Nature Medicine)^[3] tested a distinct clinical question: can oral Foundayo maintain weight loss achieved on injectable therapy? SURMOUNT-5 completers were enrolled into two cohorts: cohort 1 (n=205) had previously taken tirzepatide; cohort 2 (n=171) had previously taken semaglutide. Participants who had achieved body-weight plateau were randomized to oral orforglipron or placebo for 52 weeks. Cohort 1 preserved a model-based estimate of 74.7% of body-weight reduction with Foundayo vs 49.2% with placebo (estimated treatment difference 25.5%; P<0.001). Cohort 2 preserved 79.3% with Foundayo vs 37.6% with placebo (estimated treatment difference 41.7%; P<0.001). The most common adverse events were — again — mild-to- moderate gastrointestinal effects.

Three independent randomized trials in three distinct populations (no T2D, T2D, post-injectable maintenance) reported the same broad AE pattern. That is the strongest possible evidence that the GI dominance and the absence of any oral-formulation-specific unique adverse event are real characteristics of the molecule, not a quirk of a single trial. For the pivotal weight-loss efficacy reframing alongside this safety review, see our patient-facing Foundayo side effects guide and the Foundayo FDA approval announcement.

Why the empty-stomach dosing window matters for the AE profile

Foundayo is the first once-daily oral non-peptide GLP-1 RA, and its absorption pharmacokinetics are uniquely sensitive to food and drink. The FDA label instructs patients to take Foundayo once daily on an empty stomach with plain water, and to wait at least 30 minutes before the first food, drink, or other oral medication^[4]. This window is enforced clinically because food in the upper GI tract reduces orforglipron absorption, and reduced absorption produces both reduced efficacy and an atypical AE pattern (less consistent steady-state exposure can produce inconsistent gastric-emptying delay, leading to clusters of bad days and good days that look nothing like the trial-reported smooth dose-response).

The practical implication is that adherence to the dosing window is itself a tolerability variable. Patients who consistently take Foundayo first thing in the morning with water, then wait 30 minutes before coffee or breakfast, tend to report an AE pattern that matches the trial profile (GI symptoms peak in the first 2 to 4 weeks of each dose step, then attenuate). Patients who take it with coffee, or take it after eating, or take it at variable times of day, report less-predictable symptoms that are harder for the prescribing clinician to titrate around.

This window has no analog in the injectable GLP-1 class. Wegovy, Zepbound, Ozempic, and Mounjaro are all once-weekly subcutaneous injections; food, drink, and oral medication timing have no meaningful effect on subcutaneous absorption. For patients evaluating Foundayo vs injectable options, the question of whether they can reliably maintain a 30-minute empty-stomach window every morning is a real piece of the product-fit decision. The Foundayo dosing and administration guide walks through the morning routine in more detail.

Common gastrointestinal adverse events: rates and timing

Across all three ATTAIN trials, the most common adverse events with Foundayo were gastrointestinal: nausea, diarrhea, constipation, vomiting, and dyspepsia (indigestion / upper abdominal discomfort). The events were mostly mild to moderate in severity, were dose-dependent (higher at 36 mg than at 12 mg or 6 mg), and concentrated during the dose-escalation period rather than the maintenance period^[1][2][3].

The clinical implication is the same as for every other GLP-1 receptor agonist: GI tolerability is the dominant tolerability challenge, and it is largely time-limited per dose step rather than persistent across the full treatment duration. Patients who can get through the 2-to-4-week adaptation window at each dose increase typically reach a tolerable steady state at the maintenance dose. Patients who cannot tolerate a particular dose step have the option of staying at the lower dose for an additional cycle, slowing the titration, or in some cases backing off to the previous dose and re-attempting the step after a stability period.

Practical mitigation strategies that work for injectable GLP-1 nausea generally translate: smaller meals, avoiding very rich or greasy foods, eating slowly, stopping at the first sign of fullness, staying hydrated, and (for nighttime nausea) avoiding large evening meals. For a deeper walkthrough of patient questions about GLP-1 GI side effects, see the GLP-1 side effects Q&A and the interactive GLP-1 side-effect timeline tool.

Class-effect warnings: thyroid, pancreatitis, gallbladder

The Foundayo FDA label carries the standard GLP-1 receptor agonist class warnings^[4]. Three are clinically load-bearing:

• Boxed warning — thyroid C-cell tumors. GLP-1 receptor agonists produced thyroid C-cell tumors in rodent studies at clinically relevant exposures. Human relevance is unclear; postmarket surveillance for medullary thyroid carcinoma has not demonstrated a clear signal. The boxed warning instructs against use in patients with a personal or family history of medullary thyroid carcinoma, or patients with Multiple Endocrine Neoplasia syndrome type 2. This is identical to the Wegovy, Ozempic, Zepbound, Mounjaro, and Saxenda labels.
• Acute pancreatitis (labeled warning). Pancreatitis has been reported across the GLP-1 class. The Foundayo label instructs prompt evaluation if pancreatitis is suspected (severe persistent abdominal pain, possibly radiating to the back) and discontinuation if pancreatitis is confirmed. The pivotal-trial event counts were small. Patients with a history of pancreatitis should discuss benefit-risk explicitly with the prescriber.
• Acute gallbladder disease (labeled warning). Cholelithiasis and cholecystitis are documented in the GLP-1 class, partly mediated by rapid weight loss itself (a known independent risk factor) and partly by direct effects on gallbladder motility. Right-upper-quadrant pain with fever or jaundice warrants prompt evaluation.

Additional labeled warnings include acute kidney injury secondary to volume contraction from severe GI losses (nausea, vomiting, diarrhea), hypersensitivity reactions (including rare anaphylaxis and angioedema), diabetic retinopathy complications in patients with type 2 diabetes (a class observation rather than a Foundayo-specific finding), and the hypoglycemia warning when combined with insulin or a sulfonylurea (discussed separately below). The label also contraindicates pregnancy and breastfeeding.

How Foundayo compares to injectable Wegovy and Zepbound

The clinically relevant comparison is whether Foundayo’s oral once-daily dosing produces a meaningfully different adverse-event profile than the established injectable once-weekly options (Wegovy = semaglutide 2.4 mg sc weekly; Zepbound = tirzepatide up to 15 mg sc weekly). On the head-to-head pivotal-trial data, the answer is mostly no.

STEP-1 (Wilding and colleagues 2021, NEJM)^[5] randomized 1,961 adults with obesity to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks. The GI adverse-event rates were dominated by nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (23.4%) on semaglutide, vs much lower rates on placebo. Treatment discontinuation due to adverse events was 7.0% on semaglutide vs 3.1% on placebo. Mean weight change was -14.9% at 68 weeks vs -2.4% on placebo.

SURMOUNT-1 (Jastreboff and colleagues 2022, NEJM)^[6] randomized 2,539 adults with obesity to once-weekly subcutaneous tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. At the 15 mg arm, nausea (29.6%), diarrhea (23.0%), constipation (16.8%), and vomiting (12.2%) dominated the AE profile^[7]. Treatment discontinuation due to adverse events ran 4.3 to 7.1% on tirzepatide vs 2.6% on placebo. Mean weight change at the 15 mg arm was -20.9% at 72 weeks vs -3.1% on placebo.

Side-by-side: Foundayo’s GI adverse-event rates land in the same broad range as semaglutide and tirzepatide. The published ATTAIN-1 numbers report the GI dominance qualitatively and the discontinuation rate quantitatively (5.3 to 10.3% on orforglipron vs 2.7% on placebo), which is comparable to STEP-1 (7.0% vs 3.1%) and slightly higher at the top end than SURMOUNT-1 (4.3 to 7.1% vs 2.6%). Weight-loss magnitude favors injectable tirzepatide at the highest dose (-20.9% vs -11.2% for Foundayo 36 mg), with semaglutide intermediate (-14.9%). The Foundayo value proposition is the oral pill route, not a superior tolerability profile. For a deeper efficacy and pricing comparison see Foundayo vs Wegovy vs Zepbound: side-by-side comparison.

Hypoglycemia risk: narrow in obesity-only, broader in T2D combination

Hypoglycemia is a labeled risk for every GLP-1 receptor agonist, but the clinical relevance is highly population- dependent. In ATTAIN-1 (adults with obesity without type 2 diabetes), clinically significant hypoglycemia was not a prominent adverse-event category — the trial population did not have the failed glucose counter- regulation that defines diabetes, and orforglipron, like other GLP-1 RAs, augments insulin secretion only in response to elevated glucose^[1]. In monotherapy for weight management in adults without diabetes, hypoglycemia is a rare event.

In ATTAIN-2 (adults with obesity and type 2 diabetes), the picture shifts. Many of these patients were also on background diabetes therapy, including in some cases insulin or sulfonylureas. The Foundayo label specifically warns: hypoglycemia risk is increased when used with insulin or insulin secretagogues such as sulfonylureas^[4]. The clinical guidance most prescribers follow is to reduce the insulin or sulfonylurea dose at Foundayo initiation, monitor blood glucose closely during titration, and adjust the secretagogue or insulin dose downward as weight loss and glycemic improvement progress.

The takeaway: for the typical Foundayo weight-management candidate (adult with obesity, no diabetes), hypoglycemia is not a meaningful day-to-day concern. For the subset of patients who also have T2D and are on insulin or a sulfonylurea, the risk is real, labeled, and managed through coordinated secretagogue or insulin dose reduction. For broader context on the orforglipron mechanism see What is orforglipron (Foundayo)?

Black box warning and contraindications

The Foundayo FDA label carries the standard GLP-1 class boxed warning for thyroid C-cell tumors, derived from rodent carcinogenicity studies in which GLP-1 receptor agonists produced thyroid C-cell tumors at clinically relevant exposures^[4]. Human relevance is unclear; postmarket surveillance across multiple GLP-1 RAs has not demonstrated a clear medullary thyroid carcinoma signal. The boxed warning nevertheless instructs:

• Do not use Foundayo in patients with a personal or family history of medullary thyroid carcinoma.
• Do not use Foundayo in patients with Multiple Endocrine Neoplasia syndrome type 2.
• Counsel patients on the potential risk and the symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).

Additional contraindications include serious hypersensitivity to orforglipron or any product component, and pregnancy. The pregnancy contraindication reflects both the absence of adequate human data and the obvious clinical reasoning that weight loss is not a treatment goal during pregnancy. Patients of childbearing potential should use effective contraception and discontinue Foundayo at least 2 months before a planned pregnancy^[4].

Patients who experience symptoms suggestive of any boxed- warning or labeled-warning event — persistent neck mass or hoarseness, severe persistent abdominal pain, right-upper- quadrant pain with fever or jaundice, severe persistent vomiting or diarrhea producing dehydration, recurrent severe hypoglycemia (in the T2D-plus-secretagogue subgroup), or signs of an allergic reaction — should contact the prescribing clinician promptly, and Foundayo should generally be discontinued pending evaluation.

What patients should know going in

Five practical takeaways for a patient evaluating Foundayo:

1. Expect GI side effects, especially in the first 2 to 4 weeks of each dose step. Nausea, mild diarrhea or constipation, and occasional vomiting are the most common. They are usually mild to moderate and resolve as the body adapts. The 36 mg maintenance dose is more tolerable for most patients after the titration has been worked through gradually.
2. Take Foundayo on an empty stomach with plain water, and wait 30 minutes before food, drink, or other oral medication. This is the load-bearing dosing instruction and is not optional for predictable efficacy and tolerability. Most patients build the morning routine: pill out of the bottle, full glass of water, set a 30-minute timer, then breakfast.
3. If you have type 2 diabetes and are on insulin or a sulfonylurea, talk to your prescriber about secretagogue or insulin dose adjustment. This is the highest-yield safety conversation specific to the T2D population. Hypoglycemia risk is managed primarily by downward-titrating the background diabetes therapy.
4. Call your prescriber for red-flag symptoms. Severe persistent abdominal pain (possible pancreatitis), right-upper-quadrant pain with fever or jaundice (possible gallbladder), persistent neck mass or unexplained persistent hoarseness (boxed thyroid warning), signs of an allergic reaction, persistent severe vomiting or diarrhea (dehydration and renal-injury risk), or recurrent severe hypoglycemia in the T2D + secretagogue subgroup. Do not wait.
5. Know that weight regain after stopping is the expected pattern for every GLP-1, not a Foundayo-specific failing. ATTAIN-MAINTAIN^[3] documented that maintenance requires continued therapy — the placebo arm regained a substantial fraction of prior loss within 52 weeks. If you plan to stop, plan the off-ramp with your clinician.

Bottom line

The three pivotal ATTAIN trials — ATTAIN-1 in adults with obesity without diabetes^[1], ATTAIN-2 in adults with obesity and type 2 diabetes^[2], and ATTAIN-MAINTAIN in switch-and-maintain from injectable GLP-1s^[3] — converge on the same headline: Foundayo’s adverse-event profile is class-typical for a GLP-1 receptor agonist. Gastrointestinal events dominate, are mostly mild to moderate, are dose-dependent, and concentrate during the titration window. Treatment-emergent adverse-event discontinuations at the 36 mg dose run 5 to 10%, broadly comparable to high-dose Wegovy^[5] and Zepbound^[6].

The two distinctly Foundayo-relevant pieces of the safety picture: the empty-stomach dosing window is essential for predictable absorption and AE management, and hypoglycemia risk is specific to the T2D patients also on insulin or a sulfonylurea (with the standard mitigation: reduce the background secretagogue or insulin dose at initiation). The boxed thyroid C-cell tumor warning and the standard pancreatic, gallbladder, renal, allergic, and pregnancy warnings apply identically to Foundayo as they do to the rest of the GLP-1 class^[4].

For Foundayo dosing and titration logistics, see the week-by-week titration guide. For tolerability comparisons within the GLP-1 class, see the Foundayo vs Wegovy vs Zepbound comparison. For the broader oral-pill landscape including Rybelsus, see GLP-1 oral pills compared. For an interactive view of when GLP-1 side effects emerge across the titration ladder, see the GLP-1 side-effect timeline tool.